Enrique Poradosu is Chief Science & Business Off at Nuvectis Pharma, Inc. (NVCT). They have made 5 open-market trades across 1 company since 2022, most recently 2026-01-06.
CIK 0001898147
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $45K since 2022, never a sale. Across 5 scored buys the stock is up 37.9% at ninety days, and 36.7 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NVCT | 1,806,319 | $33.3M |
Shares reported on the most recent Form 4, priced at the 2026-01-09 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 60% | 60% |
| Avg Move | -1.9% | +1.9% | +37.9% |
| Alpha | -2.0% | +3.2% | +36.7% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCT | BUY | 2024-11-19 | 2024-11-20 | $4.99 | $10K | -1.6% | -10.5% | +53.3% |
| NVCT | BUY | 2024-05-10 | 2024-05-13 | $6.29 | $3K | +5.0% | +4.6% | -0.9% |
| NVCT | BUY | 2023-03-27 | 2023-03-28 | $11.55 | $6K | +10.4% | +27.4% | +41.3% |
| NVCT | BUY | 2022-05-12 | 2022-05-16 | $15.33 | $10K | -20.6% | -48.9% | -53.3% |
| NVCT | BUY | 2022-02-04 | 2022-02-08 | $3.44 | $16K | -3.0% | +36.8% | +149.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.